---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-016575"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2021-12-07T23:59:59+00:00"
generated_at: "2026-06-28T03:12:50.989277+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx reports positive Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia; 6/7 patients improved

## Summary
- 6 of 7 participants achieved clinically meaningful improvement in xerostomia symptoms on two validated PRO measures.
- One participant maintained maximal symptom improvement score of 7 at 24 months post-treatment.
- AAV-hAQP1 well tolerated with no dose-limiting toxicities or serious adverse events reported.
- Company plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study in H2 2022.
- Target market: ~170,000 US patients with grade 2/3 RIX; no new treatments approved in >20 years.

## SEC filing metadata
- accession: 0001558370-21-016575
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2021-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837021016575/0001558370-21-016575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837021016575/mgtx-20211207x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-016575
- JSON: https://secwatch.observer/filing/0001558370-21-016575.json
- Plain text: https://secwatch.observer/filing/0001558370-21-016575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.